Masteron (Drostanolone)

Drostanolone is a 2-alpha-methylated DHT derivative that cannot be aromatized to estrogen. It exhibits moderate anabolic activity (anabolic rating: 62-130) with strong androgenic effects (androgenic rating: 25-40). Masteron acts as a competitive inhibitor of aromatase, reducing the conversion of testosterone to estradiol. It also binds strongly to sex hormone-binding globulin (SHBG), displacing testosterone and increasing free testosterone levels. Being a DHT derivative, it does not undergo 5-alpha reduction and directly activates androgen receptors in target tissues. Its muscle-hardening effect is attributed to its anti-estrogenic activity (reducing subcutaneous water), direct androgenic action on muscle fibers enhancing tone and density, and SHBG binding which potentiates the effects of co-administered testosterone.

Drostanolone Propionate reaches peak plasma levels within 24-36 hours of intramuscular injection, with a half-life of 2-3 days. Drostanolone Enanthate peaks at 48-72 hours with a half-life of 7-10 days. Both esters are metabolized hepatically through standard phase I and phase II metabolic pathways. Masteron is not hepatotoxic (no c17-alpha alkylation). The compound has moderate bioavailability from the IM depot and does not undergo first-pass hepatic metabolism. Urinary metabolites are detectable for 3-4 months.

• ✓Significant muscle hardening and density effect at lower body fat percentages
• ✓Anti-estrogenic properties (acts as a mild aromatase inhibitor)
• ✓Enhanced muscle definition and vascularity
• ✓No water retention - produces a dry, aesthetic look
• ✓Moderate strength gains without excessive mass
• ✓Improved sense of well-being, confidence, and libido (strong androgen)
• ✓Synergistic with testosterone by reducing estrogen-related sides
• ✓Does not aromatize to estrogen

• ⚠Accelerated hair loss (one of the harshest compounds for MPB due to DHT derivation)
• ⚠Acne and oily skin
• ⚠Limited mass-building potential compared to other AAS
• ⚠HPTA suppression requiring PCT
• ⚠Effects are primarily cosmetic and less noticeable above 12-15% body fat
• ⚠Potential for prostate enlargement due to potent androgenic activity
• ⚠Can mask high estrogen symptoms by binding SHBG and freeing more testosterone
• ⚠Virilization risk for female users at moderate doses

Contraindications

• 🚫Androgenetic alopecia (masteron dramatically accelerates hair loss)
• 🚫Prostate hypertrophy or elevated PSA
• 🚫Pre-existing cardiovascular disease
• 🚫Women at risk of virilization (except at very low doses under medical supervision)
• 🚫Individuals above 15% body fat expecting dramatic visual results
• 🚫Liver disease (though masteron is not hepatotoxic, general caution applies)

Masteron Propionate: Begin PCT 4-5 days after last injection. Masteron Enanthate: Begin PCT 14 days after last injection. Standard PCT: Nolvadex 20mg/day for 4-6 weeks, or Clomid 50mg/day for 3-4 weeks. Masteron is moderately suppressive; recovery is generally easier than with 19-nor compounds. HCG during cycle at standard doses (250-500IU 2x/week) supports faster recovery.

• 1.Do not expect dramatic results above 12-15% body fat; masteron shines below 10% during a cut or contest prep
• 2.Masteron may allow you to reduce or eliminate your AI entirely when combined with testosterone
• 3.If you are prone to male pattern baldness, consider a different compound; masteron is one of the harshest for hair
• 4.Masteron Prop pairs perfectly with Test Prop and Tren Ace for a short-ester cutting stack
• 5.The libido enhancement from masteron is among the strongest of any AAS; some users specifically include it in cycles for this benefit
• 6.Do not rely on "feeling good" as evidence of controlled estrogen; get bloodwork to confirm E2 levels

1. [1]Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-521.
2. [2]Drostanolone pharmacology. Clinical Endocrinology Reviews.
3. [3]Relative binding affinity of drostanolone to SHBG and AR. Steroid Biochemistry. 1990.
4. [4]Drostanolone propionate in breast cancer treatment. Oncology Reports. 1975.